MolecularMD announced that it has been acquired by ICON. MolecularMD’s extensive scientific and clinical biomarker experience expands ICON’s capabilities in molecular diagnostic testing and also adds expanded testing platforms, including next-generation sequencing and immunohistochemistry, to ICON’s laboratory service offering. MolecularMD’s specialty central laboratory offering and associated client base extends ICON’s reach into the support of precision medicine programs across all phases of drug – diagnostic co-development.
https://thefly.com/landingPageNews.php?id=2867909
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.